Benign, Borderline, and Malignant Endometrioid Neoplasia Arising in Endometriosis in Association with Tamoxifen Therapy

McCluggage WG, W G McCluggage, W. Glenn McCluggage, Bryson C, C Bryson, Christopher L. Bryson, H Lamki, Lamki H, Boyle DD, D. D. Boyle
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2000 · vol. 19(3) , pp. 276–279 · doi:10.1097/00004347-200007000-00013 · PMID:10907178 · W2069886674
article OA: closed CC0 ⤵ 30 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This report describes an endometrioid adenocarcinoma arising in ovarian endometriosis, alongside benign and borderline endometrioid adenofibroma in the same ovary, in a patient undergoing tamoxifen therapy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Tamoxifen therapy may result in a variety of endometrial proliferative lesions, including adenocarcinoma, and as recently suggested, proliferative changes within endometriosis. This report describes an endometrioid adenocarcinoma arising in ovarian endometriosis in a patient taking tamoxifen. There were also foci of benign and borderline endometrioid adenofibroma in the same ovary and a synchronous endometrioid endometrial adenocarcinoma in the uterus. The spectrum of benign, borderline, and malignant endometrioid neoplasia arising within endometriosis suggests that tamoxifen, as a result of its estrogenic effects, may cause proliferative and, in rare instances, malignant changes in endometriosis.
Full text 1,034 characters · extracted from oa-doi-fallback · click to expand
Case Reports Benign, Borderline, and Malignant Endometrioid Neoplasia Arising in Endometriosis in Association with Tamoxifen Therapy - W. G. McCluggage - C. Bryson - H. Lamki - D. D. Boyle International Journal of Gynecological Pathology 19(3):p 276-279, July 2000. Summary: Tamoxifen therapy may result in a variety of endometrial proliferative lesions, including adenocarcinoma, and as recently suggested, proliferative changes within endometriosis. This report describes an endometrioid adenocarcinoma arising in ovarian endometriosis in a patient taking tamoxifen. There were also foci of benign and borderline endometrioid adenofibroma in the same ovary and a synchronous endometrioid endometrial adenocarcinoma in the uterus. The spectrum of benign, borderline, and malignant endometrioid neoplasia arising within endometriosis suggests that tamoxifen, as a result of its estrogenic effects, may cause proliferative and, in rare instances, malignant changes in endometriosis. Copyright © 2000 Lippincott Williams & Wilkins, Inc.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

MeSH descriptors

Adenocarcinoma Carcinoma, Endometrioid Endometrial Neoplasms Endometriosis Ovarian Neoplasms Tamoxifen Adenocarcinoma Adenocarcinoma Adenocarcinoma Breast Neoplasms Breast Neoplasms Carcinoma, Endometrioid Carcinoma, Endometrioid Carcinoma, Endometrioid Endometrial Neoplasms Endometrial Neoplasms Endometriosis Estrogen Antagonists Estrogen Antagonists Fallopian Tubes

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (17)

Cited by (30)

Source provenance

europepmc
last seen: 2026-08-02T06:10:09.037253+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:13:36.046895+00:00
License: CC0 · commercial use OK